Enodar Biologic, Zymark | GenomeWeb

Enodar Biologic, Zymark

Premium

Fred Hutchinson Cancer Research Center spin-off Enodar Biologic has launched its True Discovery genomic data-analysis services for the pharmaceutical and biotechnology industries.

Components of the service, which comprises patent-pending technology licensed from the Fred Hutchinson Cancer Research Center, are indented to “reduce genomic data backlogs, to provide an independent means to verify and validate biomarker discoveries, and to identify a higher number of quality biomarkers for investigation,” Enodar said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.